Propanc Biopharma, Inc.

Previous wording

The following discussion and analysis of the results of operations and financial condition of Propanc Biopharma, Inc., and its wholly-owned Australian subsidiary, Propanc PTY LTD (collectively, “Propanc” or the “Company”) as of December 31, 2024 and for the six months ended December 31, 2024 and 2023 should be read in conjunction with our unaudited financial statements and the notes to those unaudited financial statements that are included elsewhere in this Quarterly Report on Form 10-Q for the period ended December 31, 2024 (this “Quarterly Report”). References in this Management’s Discussion and Analysis of Financial Condition and Results of Operations section to “us”, “we”, “our” and similar terms refer to Propanc. This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “feel”, “forecast”, “intend”, “may,”, “outlook”, “plan”, “potential”, “predict”, “project,”, “seek”, “should”, “will”, “would” and their opposites and similar expressions, are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based.

Current wording

The following discussion and analysis of the results of operations and financial condition of Propanc Biopharma, Inc., and its wholly-owned Australian subsidiary, Propanc PTY LTD (collectively, “Propanc” or the “Company”) as of March 31, 2025 and for the nine months ended March 31, 2025 and 2024 should be read in conjunction with our unaudited financial statements and the notes to those unaudited financial statements that are included elsewhere in this Quarterly Report on Form 10-Q for the period ended March 31, 2025 (this “Quarterly Report”). References in this Management’s Discussion and Analysis of Financial Condition and Results of Operations section to “us”, “we”, “our” and similar terms refer to Propanc. This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The events described in forward-looking statements contained in this Quarterly Report may not occur. Generally, these statements relate to business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected or anticipated benefits from acquisitions to be made by us, or projections involving anticipated revenues, earnings or other aspects of our operating results. The words “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “feel”, “forecast”, “intend”, “may,”, “outlook”, “plan”, “potential”, “predict”, “project,”, “seek”, “should”, “will”, “would” and their opposites and similar expressions, are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, which may influence the accuracy of the statements and the projections upon which the statements are based.

Previous wording

On October 30, 2024, we filed an S-1 registration statement with the Securities and Exchange Commission for an underwritten offering that reflects the proposed reverse split of the outstanding Common Stock and treasury stock of the Company at an assumed 1- for- 60,000 ratio, which is anticipated to occur prior to the closing of the offering. Our Common Stock is currently quoted on the OTC Pink Marketplace operated by the OTC Markets Group Inc. (“OTC”) under the symbol “PPCB.” In connection with this offering, we have applied to have our Common Stock listed on the Nasdaq Capital Market under the symbol “PPCB.” The Reverse Stock Split became effective as of January 29, 2025. Proportional adjustments for the Reverse Stock Split were made to the Company’s outstanding stock options, warrants and equity incentive plans. All share and per-share data and amounts have been retroactively adjusted as of the earliest period presented in the consolidated financial statements to reflect the Reverse Stock Split.

Current wording

On October 30, 2024, we filed an S-1 registration statement with the Securities and Exchange Commission for an underwritten offering that reflects the proposed reverse split of the outstanding Common Stock and treasury stock of the Company at an assumed 1- for- 60,000 ratio, which is anticipated to occur prior to the closing of the offering. Our Common Stock is currently quoted on the OTC Pink Marketplace operated by the OTC Markets Group Inc. (“OTC”) under the symbol “PPCB.” In connection with this offering, we have applied to have our Common Stock listed on the Nasdaq Capital Market under the symbol

Previous wording

For the six months ended December 31, 2024 and 2023, we generated no revenue because we are currently undertaking research and development activities for market approval and no sales were generated in this period.

Current wording

For the three and nine months ended March 31, 2025 and 2024, we generated no revenue because we are currently undertaking research and development activities for market approval and no sales were generated in this period.

Previous wording

Administration expense decreased to $374,352 for the six months ended December 31, 2024 as compared to $712,013 for the six months ended December 31, 2023. This decrease of approximately $338,000 is primarily attributable to a decrease of approximately $227,000 in general consulting, legal and investor relation fees, decrease in accounting fees of approximately $2,000, decrease of approximately $96,000 in employee remuneration expense, decrease marketing expense of approximately $26,000 and decrease in other general and administrative expenses of approximately $2,000 offset by increase in stock-based expenses of approximately $15,000.

Current wording

Administration expense increased to $53,442,499 for the nine months ended March 31, 2025 as compared to $1,060,854 for the nine months ended March 31, 2024. This increase of approximately $52,382,000 is primarily attributable to the increase in stock-based compensation expenses of approximately $37,800,000 to our officers and an employee, stock based consulting and legal services of approximately $15,053,000 and increase in other general and administrative expenses of approximately $2,700 offset by decrease of approximately $303,000 in general consulting, legal and investor relation fees, decrease in accounting fees of approximately $1,000, decrease of approximately $109,000 in employee remuneration expense, and decrease in marketing expense of approximately $60,000.

Previous wording

Administration expense decreased to $153,593 for the three months ended December 31, 2024 as compared to $318,185 for the three months ended December 31, 2023. This decrease of approximately $165,000 is primarily attributable to a decrease of approximately $83,000 in general consulting, legal and investor relation fees, decrease of approximately $56,000 in employee remuneration expense, decrease marketing expense of approximately $33,000 and decrease in other general and administrative expenses of approximately $3,000 offset by increase in stock-based expenses of approximately $7,000 and increase in accounting fees of approximately $3,000.

Current wording

Administration expense increased to $53,068,147 for the three months ended March 31, 2025 as compared to $348,841 for the three months ended March 31, 2024. This increase of approximately $52,719,000 is primarily attributable to the increase in stock-based compensation expenses of approximately $37,800,000 to our officers and an employee, stock based consulting and legal services of approximately $15,038,000, increase in accounting fees of approximately $2,000 and increase in other general and administrative expenses of approximately $11,000 offset by decrease of approximately $84,000 in general consulting, legal and investor relation fees, decrease of approximately $14,000 in employee remuneration expense, and decrease in marketing expense of approximately $34,000.

Previous wording

Occupancy expenses increased to $13,718 for the six months ended December 31, 2024 as compared to $13,006 for the six months ended December 31, 2023. This increase of approximately $1,000 is primarily attributable to exchange rate movements over the period when compared to the same period in 2023.

Current wording

Occupancy expenses increased to $20,187 for the nine months ended March 31, 2025 as compared to $19,584 for the nine months ended March 31, 2024. This increase of approximately $600 is primarily attributable to exchange rate movements over the period when compared to the same period in 2024.

Previous wording

Occupancy expenses decreased to $5,401 for the three months ended December 31, 2024 as compared to $5,857 for the three months ended December 31, 2023. This decrease of approximately $500 is primarily attributable to exchange rate movements over the period when compared to the same period in 2023.

Current wording

Occupancy expenses decreased to $6,469 for the three months ended March 31, 2025 as compared to $6,578 for the three months ended March 31, 2024. This decrease of approximately $100 is primarily attributable to exchange rate movements over the period when compared to the same period in 2024.

Previous wording

Research and development expenses decreased to $116,102 for the six months ended December 31, 2024 as compared to $130,264 for the six months ended December 31, 2023, a decrease in research and development expenses of approximately $14,000.

Current wording

Research and development expenses decreased to $170,199 for the nine months ended March 31, 2025 as compared to $195,712 for the nine months ended March 31, 2024, a decrease in research and development expenses of approximately $26,000.

Previous wording

Research and development expenses decreased to $54,388 for the three months ended December 31, 2024 as compared to $114,022 for the three months ended December 31, 2023, a decrease in research and development expenses of approximately $60,000.

Current wording

Research and development expenses decreased to $54,097 for the three months ended March 31, 2025 as compared to $65,448 for the three months ended March 31, 2024, a decrease in research and development expenses of approximately $11,000.

Previous wording

Interest expense decreased to $205,173 for the six months ended December 31, 2024, as compared to $442,696 for the six months ended December 31, 2023. Interest expense is primarily comprised of approximately $133,000 of debt discount amortization and interest expense from accrual of interest expense and other financing fees for a total of approximately $72,000 for the six months ended December 31, 2023. This decrease in interest expense of approximately $238,000 is primarily attributable to the decrease in amortization of debt discount of approximately $31,000 and decrease of approximately $235,000 in accretion of put premium offset by increase in accrual of interest expense.

Current wording

Interest expense decreased to $309,215 for the nine months ended March 31, 2025, as compared to $575,837 for the nine months ended March 31, 2024. Interest expense is primarily comprised of approximately $193,000 of debt discount amortization and interest expense from accrual of interest expense and other financing fees for a total of approximately $95,000 for the nine months ended March 31, 2024. This decrease in interest expense of approximately $266,000 is primarily attributable to the decrease in amortization of debt discount of approximately $53,000 and decrease of approximately $262,000 in accretion of put premium offset by increase in accrual of interest expense.

Previous wording

Interest expense decreased to $118,943 for the three months ended December 31, 2024, as compared to $264,462 for the three months ended December 31, 2023. Interest expense is primarily comprised of approximately $76,000 of debt discount amortization and interest expense from accrual of interest expense and other financing fees for a total of approximately $43,000 for the three months ended December 31, 2023. This decrease in interest expense of approximately $146,000 is primarily attributable to the decrease in amortization of debt discount of approximately $19,000 and decrease of approximately $146,000 in accretion of put premium offset by increase in accrual of interest expense.

Current wording

Interest expense decreased to $104,042 for the three months ended March 31, 2025, as compared to $133,141 for the three months ended March 31, 2024. Interest expense is primarily comprised of approximately $60,000 of debt discount amortization and interest expense from accrual of interest expense and other financing fees for a total of approximately $23,000 for the three months ended March 31, 2024. This decrease in interest expense of approximately $29,000 is primarily attributable to the decrease in amortization of debt discount of approximately $22,000 and decrease of approximately $27,000 in accretion of put premium offset by increase in accrual of interest expense.

Previous wording

Derivative expense decreased to approximately $36,000 for the six months ended December 31, 2024 as compared to approximately $123,000 for the six months ended December 31, 2023. Derivative expense decreased to approximately $9,000 for the three months ended December 31, 2024 as compared to approximately $46,000 for the three months ended December 31, 2023. This decrease is primarily attributable to the decrease in the issuance of convertible notes which initial value was bifurcated from the embedded conversion option and was recorded as derivative expense.

Current wording

Derivative expense decreased to approximately $95,000 for the nine months ended March 31, 2025 as compared to approximately $123,000 for the nine months ended March 31, 2024. This decrease is primarily attributable to the decrease in the issuance of convertible notes which initial value was bifurcated from the embedded conversion option and was recorded as derivative expense during the nine-month period.

Previous wording

Change in fair value of derivative liabilities decreased to a gain of approximately $66,000 for the six months ended December 31, 2024 as compared to a gain of approximately $302,000 for the six months ended December 31, 2023. Change in fair value of derivative liabilities were decreased to a gain of approximately $14,000 for the three months ended December 31, 2024 as compared to a loss of approximately $2,000 for the three months ended December 31, 2023. This decrease in gain of approximately $15,000 and $236,000 is primarily attributable to a decrease in fair value of the principal amount of convertible notes with bifurcated embedded conversion option derivatives as a result of the decrease in stock prices during the three and six months ended December 31, 2024, respectively.

Current wording

Change in fair value of derivative liabilities decreased to a gain of approximately $113,000 for the nine months ended March 31, 2025 as compared to a gain of approximately $372,000 for the nine months ended March 31, 2024. Change in fair value of derivative liabilities were decreased to a gain of approximately $47,000 for the three months ended March 31, 2025 as compared to a loss of approximately $70,000 for the three months ended March 31, 2024. This decrease in gain of approximately $23,000 and $259,000 is primarily attributable to a decrease in fair value of the principal amount of convertible notes with bifurcated embedded conversion option derivatives as a result of the decrease in stock prices during the three and nine months ended March 31, 2025, respectively.

Previous wording

During the six months ended December 31, 2024, notes with principal amounts totaling $49,100, accrued interest of $3,769 and conversion fees of $2,833 containing bifurcated embedded conversion option derivatives which were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $137,454, resulting in a loss on extinguishment at the time of conversion of $81,752 and $51,674 of derivative liability fair value and was recorded as a gain on extinguishment at the time of conversion, resulting in a net loss of $30,078 which is included in gain (loss) on extinguishment of debt in the accompanying condensed consolidated statements of operations.

Current wording

During the nine months ended March 31, 2025, convertible notes containing bifurcated embedded conversion option derivatives with principal aggregate amount of $54,850, accrued interest of $4,365 and conversion fees of $3,770 were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $154,154, resulting in a loss on extinguishment at the time of conversion of $91,169 and $73,640 of derivative liability fair value and was recorded as a gain on extinguishment at the time of conversion, resulting in a net loss of $17,529 which is included in gain (loss) on extinguishment of debt in the accompanying condensed consolidated statements of operations.

Previous wording

During the six months ended December 31, 2023 there were principal aggregate amount of convertible notes of $75,300, accrued interest of $5,570 and conversion fees of $1,597 containing bifurcated embedded conversion option derivatives which were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $198,753, resulting in a loss on extinguishment at the time of conversion of $116,285 and $150,384 of derivative liability fair value and was recorded as a gain on extinguishment at the time of conversion, resulting in a net gain of $34,099.

Current wording

During the nine months ended March 31, 2024, convertible notes with principal aggregate amount of $91,300, accrued interest of $11,080 and conversion fees of $2,236 containing bifurcated embedded conversion option derivatives were converted into common stock. Accordingly, the fair market value of the shares issued upon conversion was $243,286, resulting in a loss on extinguishment at the time of conversion of $143,467 and $170,785 of derivative liability fair value was recorded as a gain on extinguishment at the time of conversion, resulting in a net gain of $27,318 which is included in gain (loss) on extinguishment of debt in the accompanying condensed consolidated statements of operations during the nine months ended March 31, 2024.

Previous wording

Foreign currency transaction gain (loss) decreased to a loss of approximately ($76,000) for the six months ended December 31, 2024 as compared to a gain of approximately $21,000 for the six months ended December 31, 2023. This decrease of approximately $97,000 is partially attributable to the decrease in exchange rates during the six months ended December 31, 2024.

Current wording

Foreign currency transaction gain (loss) increased to a loss of approximately ($88,000) for the nine months ended March 31, 2025 as compared to a loss of approximately $15,000 for the nine months ended March 31, 2024. This increase of approximately $73,000 is primarily attributable to the decrease in exchange rates during the nine months ended March 31, 2025.

Previous wording

Foreign currency transaction gain (loss) decreased to a loss of approximately ($84,000) for the three months ended December 31, 2024 as compared to a gain of approximately $37,000 for the three months ended December 31, 2023. This decrease of approximately $121,000 is partially attributable to the decrease in exchange rates during the three months ended December 31, 2024.

Current wording

Foreign currency transaction gain (loss) decreased to a loss of approximately ($12,000) for the three months ended March 31, 2025 as compared to a gain of approximately $36,000 for the three months ended March 31, 2024. This increase of approximately $24,000 is primarily attributable to the decrease in exchange rates during the three months ended March 31, 2025.

Previous wording

Net loss decreased to $784,493 for the six months ended December 31, 2024 as compared to a net loss of $935,250 for the six months ended December 31, 2023. Net loss decreased to $430,183 for the three months ended December 31, 2024 as compared to a net loss of $584,384 for the three months ended December 31, 2023. The change relates to the factors discussed above.

Current wording

Net loss increased to $54,851,839 for the nine months ended March 31, 2025 as compared to a net loss of $1,461,950 for the nine months ended March 31, 2024. Net loss increased to $54,067,346 for the three months ended March 31, 2025 as compared to a net loss of $526,700 for the three months ended March 31, 2024. The change relates to the factors discussed above.

Previous wording

The Company recognized the value of the effect of a down-round feature related to our Series A warrants when triggered. Upon the occurrence of the triggering event that resulted in a reduction of the strike price, the Company measured the value of the effect of the feature as the difference between the fair value of the warrants without the down round feature or before the strike price reduction and the fair value of the warrants with a strike price corresponding to the reduced strike price upon the down round feature being triggered. Accordingly, the Company recognized deemed dividend of $0 and $177,160 during the six months ended December 31, 2024 and 2023, respectively, $0 and $128,620 during the three months ended December 31, 2024 and 2023, respectively, and a corresponding reduction of income available to common stockholders upon the alternate cashless exercise of these warrants during the three and six months ended December 31, 2024 and 2023.

Current wording

The Company recognized the value of the effect of a down-round feature related to our Series A warrants when triggered. Upon the occurrence of the triggering event that resulted in a reduction of the strike price, the Company measured the value of the effect of the feature as the difference between the fair value of the warrants without the down round feature or before the strike price reduction and the fair value of the warrants with a strike price corresponding to the reduced strike price upon the down round feature being triggered.

Previous wording

Net loss available to common stockholders decreased to $784,493 for the six months ended December 31, 2024 as compared to a net loss available to common stockholders of $1,112,410 for the six months ended December 31, 2023. Net loss available to common stockholders decreased to $430,183 for the three months ended December 31, 2024 as compared to a net loss available to common stockholders of $618,969 for the three months ended December 31, 2023. This decrease of approximately $189,000 and $328,000 during the three months ended December 31, 2024 and 2023, respectively, is primarily attributable to the change relates to the factors discussed above.

Current wording

Net loss available to common stockholders increased to $54,851,839 for the nine months ended March 31, 2025 as compared to a net loss available to common stockholders of $1,654,910 for the nine months ended March 31, 2024. Net loss available to common stockholders increased to $54,067,346 for the three months ended March 31, 2025 as compared to a net loss available to common stockholders of $542,500 for the three months ended March 31, 2024. This increase of approximately $53,525,000 and $53,197,000 during the three and nine months ended March 31, 2025 and 2024, respectively, is primarily attributable to the change related to the factors discussed above.

Previous wording

As of December 31, 2024, we had total assets of $78,533, comprised primarily of cash of $14,633, GST tax receivable of $1,973, prepaid expenses and other current assets of $1,378, security deposit of $1,855, and operating lease ROU asset, net of $6,577. As compared to June 30, 2024, we had total assets of $72,365, comprised primarily of cash of $21,085, GST tax receivable of $2,950, prepaid expenses and other current assets of $1,406, deferred offering cost of $27,117, security deposit of $2,008, and operating lease ROU asset, net of $17,799.

Current wording

As of March 31, 2025, we had total assets of $22,527,352, comprised primarily of cash of $50,760, GST tax receivable of $3,633, prepaid expenses – current portion of $9,680,347, other current assets of $1,312, security deposit of $1,874, deferred offering cost of $92,117, prepaid expenses – long-term of $12,695,648, and operating lease ROU asset, net of $1,661. As compared to June 30, 2024, we had total assets of $72,365, comprised primarily of cash of $21,085, GST tax receivable of $2,950, prepaid expenses and other current assets of $1,406, deferred offering cost of $27,117, security deposit of $2,008, and operating lease ROU asset, net of $17,799.

Previous wording

We had current liabilities of $4,154,964, primarily comprised of net convertible debt of $409,799, accounts payable and accrued expenses of $2,257,867, employee benefit liability of $611,318, loans payable of $145,091, loans payable-related parties of $350,544, note payable, net of $168,217 and embedded conversion option liabilities of $131,585 as of December 31, 2024. As compared to June 30, 2024, we had current liabilities of $3,792,782, primarily comprised of net convertible debt of $399,325, accounts payable and accrued expenses of $2,100,137, employee benefit liability of $639,371, loans payable of $145,091, loans payable – related party of $71,629, note payable, net of $204,694 and embedded conversion option liabilities of $133,886 as of June 30, 2024.

Current wording

We had current liabilities of $4,341,147, primarily comprised of net convertible debt of $438,578, accounts payable and accrued expenses of $2,203,846, employee benefit liability of $624,682, loans payable of $65,280, loans payable-related parties of $366,029, note payable, net of $281,508 and embedded conversion option liabilities of $191,770 as of March 31, 2025. As compared to June 30, 2024, we had current liabilities of $3,792,782, primarily comprised of net convertible debt of $399,325, accounts payable and accrued expenses of $2,100,137, employee benefit liability of $639,371, loans payable of $145,091, loans payable – related party of $71,629, note payable, net of $204,694 and embedded conversion option liabilities of $133,886 as of June 30, 2024.

Previous wording

During the six months ended December 31, 2024 we received proceeds from issuance of notes of $115,000 and proceeds from issuance of loan payable from related parties of $278,915.

Current wording

During the nine months ended March 31, 2025 we received proceeds from issuance of notes of $145,000, proceeds from convertible notes of $150,000, and proceeds from issuance of loan payable from related parties of $294,400.

Previous wording

We have substantial capital resource requirements and have incurred significant losses since inception. As of December 31, 2024, we had $14,633 in cash. We depend upon debt and/or equity financing to fund our ongoing operations and to execute our current business plan. Such capital requirements are in excess of what we have in available cash and for which we currently have commitments. Therefore, we presently do not have enough available cash to meet our obligations over the next 12 months. If continued funding and capital resources are unavailable at reasonable terms, we may curtail our plan of operations. We will be required to obtain alternative or additional financing from financial institutions, investors or otherwise, in order to maintain and expand our existing operations. The failure by us to obtain such financing would have a material adverse effect upon our business, financial condition and results of operations, and adversely affecting our ability to complete ongoing activities in connection with our research and development programs.

Current wording

We have substantial capital resource requirements and have incurred significant losses since inception. As of March 31, 2025, we had $50,760 in cash. We depend upon debt and/or equity financing to fund our ongoing operations and to execute our current business plan. Such capital requirements are in excess of what we have in available cash and for which we currently have commitments. Therefore, we presently do not have enough available cash to meet our obligations over the next 12 months. If continued funding and capital resources are unavailable at reasonable terms, we may curtail our plan of operations. We will be required to obtain alternative or additional financing from financial institutions, investors or otherwise, in order to maintain and expand our existing operations. The failure by us to obtain such financing would have a material adverse effect upon our business, financial condition and results of operations, and adversely affecting our ability to complete ongoing activities in connection with our research and development programs.

Previous wording

Net cash used in operating activities was $572,342 for the six months ended December 31, 2023, due to our net loss of $935,250 offset primarily by non-cash charges of amortization of debt discount of $164,904, non-cash interest expense of $1,597, accretion of put premium of $234,615, derivative expense of $123,379, foreign currency transaction gain of $21,198, addback change in fair value of derivatives of $302,158 and gain from extinguishment of debt of $34,099. Net changes in operating assets and liabilities totaled $184,749, which is primarily attributable to an increase in prepaid expense of $5,877, increase in refundable advance deposit of $123,127, increase accrued interest of $35,323, increase in accounts payable of $169,359, and increase in accrued expenses and other payables of $96,924.

Current wording

Net cash used in operating activities was $377,982 for the nine months ended March 31, 2025, due to our net loss of $54,851,839 offset primarily by non-cash charges of amortization of debt discount of $193,283, non-cash interest expense of $5,519, total stock-based expenses of $52,853,115, derivative expense of $95,012, foreign currency transaction loss of $88,184, and loss from extinguishment of debt of $840,032 addback change in fair value of derivatives of $113,487. Net changes in operating assets and liabilities totaled $497,247, which is primarily attributable to an increase in accrued interest of $89,179, increase in accounts payable of $118,706 and increase in accrued expenses and other payables of $342,223 offset by increase in deferred offering cost of $65,000.

Previous wording

Net cash used in operating activities was $241,786 for the six months ended December 31, 2024, due to our net loss of $784,493 offset primarily by non-cash charges of amortization of debt discount of $133,644, non-cash interest expense of $4,582, derivative expense of $35,741, foreign currency transaction loss of $75,698, and gain from extinguishment of debt of $30,078 addback change in fair value of derivatives of $66,368. Net changes in operating assets and liabilities totaled $304,466, which is primarily attributable to an increase in accrued interest of $49,350, increase in accounts payable of $102,374 and increase in accrued expenses and other payables of $166,993.

Current wording

Net cash used in operating activities was $675,152 for the nine months ended March 31, 2024, due to our net loss of $1,461,950 offset primarily by non-cash charges of amortization of debt discount of $246,612, non-cash interest expense of $2,236, accretion of put premium of $261,538, derivative expense of $123,379, foreign currency transaction loss of $15,228, addback change in fair value of derivatives of $372,371 and gain from extinguishment of debt of $27,318. Net changes in operating assets and liabilities totaled $521,602, which is primarily attributable to increase accrued interest of $57,823, increase in accounts payable of $242,466, and increase in accrued expenses and other payables of $198,995.

Previous wording

Net cash provided by financing activities for the six months ended December 31, 2024 was $295,515. During the six months ended December 31, 2024 we received net proceeds from issuance of convertible notes of $80,000, proceeds from a note of $35,000 and proceeds from issuance of loan from related parties of $278,915 offset by repayment of notes of $98,400.

Current wording

Net cash provided by financing activities for the nine months ended March 31, 2025 was $483,000. During the nine months ended March 31, 2025 we received net proceeds from issuance of convertible notes of $150,000, proceeds from a note of $145,000 and proceeds from issuance of loan from related parties of $294,400 offset by repayment of notes of $98,400 and convertible note of $8,000.

Previous wording

Net cash provided by financing activities for the six months ended December 31, 2023 were $624,276. During the six months ended December 31, 2023 we received net proceeds from issuance of convertible notes of $477,500, proceeds from issuance of note of $120,000, proceeds from issuance of loans from a related party of $169,685 offset by repayment of convertible note of $142,909.

Current wording

Net cash provided by financing activities for the nine months ended March 31, 2024 were $690,920 as compared to $1,013,719 for the nine months ended March 31, 2023. During the nine months ended March 31, 2024 we received net proceeds from issuance of convertible notes of $516,875, proceeds from issuance of note of $120,000, proceeds from issuance of loans from a related party of $185,872, proceeds from the sale of shares of our common stock of $11,082 offset by repayment of convertible note of $142,909.

Previous wording

The effect of the exchange rate on cash resulted in a $60,181 negative adjustment to cash flows in the six months ended December 31, 2024 as compared to a $9,669 positive adjustment to cash flows in the six months ended December 31, 2023. The reason for the fluctuation is due to the application of currency translation rates throughout the cash flow statement, the volume of transactions within each period and the daily fluctuation in exchange rates.

Current wording

The effect of the exchange rate on cash resulted in a $75,343 negative adjustment to cash flows in the nine months ended March 31, 2025 as compared to a $19,593 negative adjustment to cash flows in the nine months ended March 31, 2024. The reason for the fluctuation is due to the application of currency translation rates throughout the cash flow statement, the volume of transactions within each period and the daily fluctuation in exchange rates.

Previous wording

We did not generate any revenue for the six months ended December 31, 2024 and 2023 and have incurred significant losses and cash used in operations, and such losses and use of cash are expected to continue. Our independent registered public accounting firm has included a “Going Concern Qualification” in their audit report for each of the fiscal years ended June 30, 2024 and 2023. In addition, we have negative working capital and convertible debt that is past maturity that we are currently negotiating with lenders in order to amend the maturity dates. The foregoing raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. Our ability to continue as a going concern is dependent on our ability to execute our strategy and on our ability to raise additional funds and/or to consummate a public offering. Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity and/or convertible debt financing. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.

Current wording

We did not generate any revenue for the nine months ended March 31, 2025 and 2024 and have incurred significant losses and cash used in operations, and such losses and use of cash are expected to continue. Our independent registered public accounting firm has included a “Going Concern Qualification” in their audit report for each of the fiscal years ended June 30, 2024 and 2023. In addition, we have negative working capital and convertible debt that is past maturity that we are currently negotiating with lenders in order to amend the maturity dates. The foregoing raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. Our ability to continue as a going concern is dependent on our ability to execute our strategy and on our ability to raise additional funds and/or to consummate a public offering. Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stockholders, in case of equity and/or convertible debt financing. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.